Jaime Vieser has made a notable move by acquiring additional shares in Alaunos Therapeutics, Inc., according to a recent SEC filing. This acquisition, reported on October 8, 2026, is significant as it reflects Vieser’s commitment to the company and its future prospects.
Vieser, who serves as a director at Alaunos Therapeutics, purchased 22,669 shares on October 6, 2026, at a price of $0.7444 per share. Following this transaction, he now owns a total of 70,311 shares directly. Additionally, he holds 2,100 shares indirectly through his children and 13,503 shares through Brushwood LLC, where he is the manager.
Background
Alaunos Therapeutics, Inc. operates in the pharmaceutical preparations sector. The company is incorporated in Delaware and is listed under the trading symbol TCRT. Its business address is located at 501 E Las Olas Blvd, Suite 300, Fort Lauderdale, FL.
What the Filing Says
The SEC filing details Vieser’s acquisition of shares, stating, "Represents shares of common stock issued in lieu of board fees." This indicates that part of the transaction was related to his compensation as a board member.
Impact
This increase in ownership may have implications for Alaunos Therapeutics, particularly regarding its strategic direction and investor confidence. As a director, Vieser’s financial commitment could signal to other investors that he believes in the company’s future potential.
What's Next
The filing does not say what happens next.